ARTHROPLASTY
Similar extended VTE prophylaxis efficacy and safety between rivaroxaban and aspirin following TJA
N Engl J Med. 2018 Feb 22;378(8):699-7073427 patients who had undergone either total knee or hip arthroplasty with a 5-day course of rivaroxaban 10mg postoperatively were randomized to extended thromboprophylaxis with either aspirin 81mg daily or continued rivaroxaban 10mg daily. Patients were assessed for the incidence of venous thromboembolism, major bleeding events, and clinically relevant nonmajor bleeding events over the first 90 days after surgery. Noninferiority analysis for efficacy demonstrated that extended aspirin was noninferior to extended rivaroxaban. Groups also demonstrated no significant difference in the incidence of bleeding events.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
